Trial Results Reveal Weight Loss
Adults taking Eli Lilly and Co.’s experimental drug EloraTZP lost an average of 23.3% of their body weight after 48 weeks, according to data released on Saturday at the ObesityWeek 2026 medical conference.
The phase 2 trial data, which have not yet been published in full, evaluated the combination treatment of eloralintide and tirzepatide in overweight or obese adults with type 2 diabetes. Participants dropped an average of 54.10 pounds from a starting weight of 232.40 pounds, Investing reported.
Up to 60% of trial participants taking the drug no longer met the body mass index criteria for obesity by the end of the 48-week period. The treatment also lowered hemoglobin A1C levels by an average of 2.90%, with 77% of participants achieving normal blood sugar levels.
“We saw a reduction in cravings, especially for sugary foods,” during phase 2 exit interviews, Investing reported, noting that 74% of participants reported this decrease over 48 weeks, while 52% noted a drop in food noise.
Adolescent Zepbound Study Outcomes
Eli Lilly also released phase 3 data from its SURMOUNT-ADOLESCENTS trial testing Zepbound in minors aged 12 to 18. The treatment reduced body mass index by an average of 21.40% after 72 weeks in obese adolescents.
More than half of the young participants no longer met obesity BMI criteria after completing the 72-week regimen. Participants experienced improvements in weight-related quality of life, including physical comfort and body image self-esteem.
Frequently Asked Questions
What is EloraTZP and how does it work?
EloraTZP is an experimental phase 2 combination drug that pairs eloralintide with tirzepatide. In clinical trials, it targeted both weight reduction and blood sugar control in adults with type 2 diabetes and obesity.
How long did the Zepbound trial for adolescents last?
The SURMOUNT-ADOLESCENTS trial for Zepbound lasted for 72 weeks. It evaluated participants between the ages of 12 and 18 who lived with obesity.
What specific health improvements were tracked alongside weight loss?
Trials tracked hemoglobin A1C reductions, normalized blood sugar levels, and improvements in weight-related quality of life.
Related reading